ABCL
Abcellera Biologics Inc.
A Vancouver biotech company that hunts for new medicines by mining the immune system's own antibodies. Using microfluidics, single-cell screening and machine learning, it sifts through millions of immune cells to find antibodies that drug partners like Eli Lilly can turn into treatments. Born in 2012 out of University of British Columbia research, its name blends "Ab" (the shorthand for antibody) with "cell." During the pandemic it helped find an antibody from a recovered COVID-19 patient's blood sample that became part of a widely used treatment.
CUSIP: 00288U106HealthcareUS1 holder
Total Value
$32.22M
Total Shares
4.11M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
